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The hepatitis B virus HBx protein is a promiscuous
transactivator implicated in the development of hepato-
cellular carcinoma. The ectopic expression of HBx fails
to transform both primary and immortalized rodent cells,
but rather induces apoptosis. Furthermore, most trans-
genic mice harboring HBx do not develop liver tumors.
Thus, it remains unclear whether and how HBx
contributes to oncogenesis. Here, we show that HBx
collaborates with activated H-ras to transform immorta-
lized rodent cells. Indeed, REF52 cells transfected by
both HBx and activated H-ras were morphologically
transformed and were able to grow in soft agar.
Remarkably, nude mice injected with REF52 cells
transfected by both HBx and activated H-ras developed
tumors, whereas the mice injected with REF52 cells
transfected by either gene alone did not. Thus, we
concluded that HBx could contribute to neoplastic
transformation of cells in collaboration with other
oncogenes, such as H-ras, that renders cells to overcome
the HBx-mediated apoptosis. Further, we found that
HBx mediated apoptosis was suppressed by activated H-
ras through activation of the phosphatidylinositol-3
kinase and Akt pathway. Data presented here firmly
established the oncogenic potential of HBx during
multistage carcinogenesis. Oncogene (2001) 20, 16 – 23.
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Introduction
Hepadnaviruses is a family of small enveloped DNA
viruses characterized by their pronounced liver tropism
(Ganem and Varmus, 1987). Human hepatitis B virus
(HBV), a prototype member of the family, is a leading
cause of acute and chronic viral hepatitis in humans
worldwide. Earlier epidemiological evidence has in-
dicated that chronic HBV infection is the major
etiological factor of the hepatocellular carcinoma
(HCC) (Beasley et al., 1981). Despite the compelling
epidemiological evidence, to what extent the viral gene
products contribute to hepatocarcinogenesis is still in
question. Animal models of hepadnaviruses including
woodchuck hepatitis virus (WHV) and ground squirrel
hepatitis virus (GSHV) have been invaluable to further
substantiate the link between HBV infection and HCC
(Buendia, 1992). It was noted that three mammalian
hepadnaviruses share a regulatory gene termed X,
whereas no counterpart of this gene is found in the
distantly related nononcogenic duck hepatitis B virus
(DHBV) (Ganem and Varmus, 1987). The HBx, a 154
amino acid gene product of the X gene, has been
known as a promiscuous transcriptional transactivator
since it is capable of transactivating gene expression by
acting on a wide range of viral and cellular regulatory
elements (Yen, 1996). This led to suggest that HBx
might play a role in liver carcinogenesis. Until recently,
its role during the infection cycle remained elusive,
since HBx has been shown to be dispensable for viral
genome replication in tissue culture (Blum et al., 1992).
Subsequently, the requirement of HBx gene product
for productive viral infection has been firmly estab-
lished in the woodchuck model (Chen et al., 1993;
Zoulim et al., 1994). Thus, HBx is an essential viral
protein during the viral infection cycle in vivo, although
its specific function pertaining to the infection cycle
still remains unknown.
On the other hand, transcriptional transactivator
properties of HBx have been demonstrated on a variety
of viral and cellular regulatory elements (Yen, 1996).
HBx does not directly bind to DNA and may stimulate
transcription by interacting with transcription factors
or with the basal transcription machinery of host RNA
polymerase II and III (Cheong et al., 1995; Haviv et
al., 1998; Maguire et al., 1991; Qadri et al., 1996;
Williams and Andrisani, 1995). Besides its nuclear
function as a transcriptional transactivator, several
studies indicated that HBx influences cellular signaling
pathways in the cytoplasm as well, which is a function
consistent with the predominant cytoplasmic localiza-
tion of HBx in vivo and in most experimental systems
(Benn and Schneider, 1994; Natoli et al., 1994). It has
been shown that HBx activates ras in vivo, inducing a
cytoplasmic signaling cascade linking ras, raf, and
MAP kinases, which leads to transcriptional transacti-
vation and the stimulation of proliferation in quiescent
cells (Benn and Schneider, 1994; Natoli et al., 1994).
On the other hand, it was reported that HBx either
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induces apoptosis or sensitizes cells to apoptotic stimuli
(Chirillo et al., 1997; Kim et al., 1998; Su and
Schneider, 1997). In addition, HBx has been shown
to activate transcriptional factors NF-kB (Chirillo et
al., 1996; Lucito and Schneider, 1992; Su and
Schneider, 1996), and src oncogene (Klein and
Schneider, 1997). More recently, HBx was shown to
activate Jak/stat signaling as well (Lee and Yun, 1998).
Regarding its cellular location, dual role of HBx has
been demonstrated, that is, a nuclear function as a
transcriptional transactivator as well as a cytoplasmic
function as an activator of mitogenic signaling (Doria
et al., 1995). Thus, HBx has pleiotropic activities that
might involve in viral pathogenesis and carcinogenesis.
Numerous attempts have been made to examine the
oncogenic potential of HBx in cell culture (Hohne et
al., 1990; Oguey et al., 1996; Shirakata et al., 1989;
Tarn et al., 1999). However, its transforming ability
was barely measurable only when cells were immorta-
lized by other oncogenes, such as SV40 T-antigen
(Hohne et al., 1990) or TGF-a (Oguey et al., 1996;
Tarn et al., 1999). Further, most transgenic mouse
harboring the HBx gene did not result in serious liver
diseases or tumors (Billet et al., 1995; Guidotti et al.,
1995; Koike et al., 1994a; Lee et al., 1990). Only in
certain transgenic lineage of CD-1 strain, HBx weakly
promoted tumorigenesis, where HBx was expressed at
high levels (Kim et al., 1991). Nonetheless, a second
mouse lineage with lower HBx expression developed
liver tumors at the same rate as the normal CD-1
mouse (Koike et al., 1994a). In addition, HBx was
shown to potentiate c-myc-induced liver oncogenesis in
transgenic mice (Terradillos et al., 1997). Taken
together, data obtained from these transgenic studies
suggested that HBx had no acute transforming activity,
but its overexpression in a certain genetic background
might induce tumor formation, possibly in collabora-
tion with activated cellular oncogene(s) in multistage
transformation. Although it is generally believed that
HBx is a cofactor in hepatocarcinogenesis (Dandri et
al., 1996; Paterlini et al., 1995; Su et al., 1998), direct
evidence for oncogenic contribution of HBx is still
lacking.
To examine the oncogenic potential of the HBx
protein, we tested whether HBx collaborates with other
oncogenes to transform cells using several assay
methods including colony formation assay, morpholo-
gical change, anchorage independent growth in soft
agar, and tumor formation in nude mouse. In contrast
to a previous report (Kim et al., 1998; Schuster et al.,
2000), significant collaboration between HBx and
activated H-ras oncogene was observed. Our observa-
tion that HBx mediated apoptosis was suppressed by
activated H-ras underlies the molecular basis of the
collaboration between HBx and H-ras. Importantly, we
demonstrated that REF52 cells transfected by both
HBx and H-ras were morphologically transformed and
had the ability to grow on soft agar. Remarkably, nude
mice injected with HBx and H-ras cotransfected
REF52 cells developed tumors, whereas the mice
injected with REF52 cells transfected by either gene
alone did not. These data demonstrating the oncogenic
activity of HBx define its role during the multistage
carcinogenesis.
Results
HBx gene collaborates with H-ras to transform cells
To investigate the role of HBx in oncogenesis, we
examined the transforming ability of HBx by colony
formation assay. Rat2 cells were transfected by various
combinations of HBx and other oncogenes and selected
for G418 resistance (Table 1). As expected, cotransfec-
tion of the ras and myc gene in Rat2 cells resulted in a
higher number of colonies than when H-ras was
transfected alone. On the other hand, consistent with
other reports (Chirillo et al., 1997; Kim et al., 1998),
only a few colonies were observed when cells were
transfected with the HBx expression plasmid alone.
This number is even smaller than that resulting from
the pSV2neo control, suggesting that HBx might have
induced apoptosis. Interestingly, cotransfection of HBx
and H-ras expression plasmids yielded significantly
higher number of colonies than either HBx or H-ras
Figure 1 Colony formation assay in NIH3T3 cells. The result
from a typical experiment is shown. The amount of plasmid DNA
transfected is indicted in parentheses. HBx, pSV-X(SV40 early
promoter); H-ras, pEJ 6.6 (H-ras)
Table 1 Colony formation assay of Rat2 and NIH3T3 cells
Number of coloniesa
Exp. 1 Exp. 2
Transfected genes (1 mg) Rat2 NIH3T3 Rat2 NIH3T3
Neo only ndb nd 27 12
HBx 10 1 2 2
H-ras 28 25 25 47
H-ras+HBx 49 47 74 39
H-ras+myc 48 53 43 45
aThe number of colonies formed (40.2 mm in diameter) was counted
2 – 3 weeks after transfection. bnd, not determined
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alone did, comparable to that with H-ras plus myc
(Table 1). Thus, it appeared that HBx significantly
collaborated with the activated H-ras to transform
Rat2 cells. Similar results were obtained with NIH3T3
cells (Figure 1 and Table 1). Our result is not
consistent with a previous observation that the ectopic
expression of HBx using the CMV promoter sup-
pressed colony formation by other oncogenes including
H-ras (Kim et al., 1998). Our own experiment using
CMV promoter also agreed with the previous report
(data not shown). On the other hand, in our
experiment using the moderate SV40 promoter to
express HBx, we observed a measurable collaboration
between HBx and H-ras (Table 1). Given that HBx is
present in hepatocyte of infected animal at a very low
copy number (less than 40 000 – 80 000 molecules per
cell) (Dandri et al., 1996), an experiment using a
moderate SV40 promoter is more likely to reflect the
physiological concentration of HBx in hepatocytes.
Thus, subsequent experiments were carried out using
the SV40 promoter to express the HBx protein.
H-ras oncogene suppresses HBx mediated apoptosis
Since HBx can induce apoptosis upon various stimuli
(Chirillo et al., 1997; Kim et al., 1998; Su and
Schneider, 1997), it is possible that the HBx-induced
apoptosis was suppressed by the cotransfected H-ras.
To substantiate this notion, apoptosis assays were
performed with cells derived from the above foci. Cell
death was measured either by trypan blue staining for
viable cells or by agarose gel electrophoresis analysis
for DNA fragmentation (Figure 2). When cells were
treated with a lower concentration of etoposide
(10 mM), cell viability of parental NIH3T3 cells were
not aected. In contrast, cell death was evident in the
NIH-HBx cells (Figure 2a). On the other hand, cell
viability was reduced even in parental NIH3T3 cells if
cells were treated with a higher concentration of
etoposide (100 mM). The result indicated that HBx
sensitized cells to apoptosis upon DNA damage.
Interestingly, we found that cell viability were not
significantly reduced in NIH3T3 cells transfected with
HBx plus H-ras, even when cells were treated with a
Figure 2 Evidence that the ectopic expression of H-ras inhibits
HBx-mediated apoptosis. (a) Viable cell counts after trypan blue
staining. Cells were plated in DMEM containing 5% FBS at a
density of 36105 cells/60 mm plate: NIH3T3(*), NIH-HBx(~),
NIH-HBx+ras(^), NIH-HBx+Bcl-2(&). At 24 h, the cells were
treated with the indicated concentration of etoposide. After
another 24 h of incubation, the cells were stained in PBS
containing 0.04% trypan blue solution and counted with a
hemacytometer. (b) Analysis of DNA fragmentation after etopo-
side treatment. Cells were plated in DMEM containing 5% FBS
at a density of 16106 cells per 100 mm plate. Next day, the cells
were treated with 10 mM of etoposide for an additional 1 day.
Both adherent and floating cells were collected and DNAs were
prepared and subjected to electrophoresis in 1.4% agarose gels.
(c) Western blot analysis of HBx protein. HBx protein was
detected by immunoblotting with rabbit polyclonal anti-HBx
peptide (residue 144 – 154). HBx protein, 17 kDa, is indicated by
an arrow
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higher concentration of etoposide (100 mM). It is noted
that the extent of protection against the etoposide-
induced apoptosis by H-ras was comparable to that by
Bcl-2 (Figure 2a). In addition, DNA fragmentation
analysis results were consistent with those of viable cell
counts (Figure 2b). Likewise, upon serum starvation,
apoptosis was observed in the NIH-HBx cells, but not
in the NIH-HBx plus H-ras cells (data not shown).
These results are consistent with the notion that the
HBx-mediated apoptosis was suppressed by H-ras. In
addition, Western blot analysis indicated that similar
levels of HBx protein were expressed in both HBx
transfected cells (Figure 2c). Thus, the possibility that
HBx expression in NIH-HBx plus H-ras cells was
suppressed by the cotransfected H-ras was excluded.
H-ras oncogene suppresses HBx mediated apoptosis
through PI(3)-Akt pathway
Next, we sought to examine the signal transduction
pathway involved in the ras-mediated suppression of
the apoptosis. Recently, it has been documented that
the activated Akt oncogene suppresses apoptosis by
phosphorylating Bad (Datta et al., 1997), a pro-
apoptotic member of the Bcl-2 family. In addition, it
was reported that the activation of Akt, induced by
ras, blocks apoptosis by phosphorylating caspase-9
(Cardone et al., 1998). Since the activated ras can
activate Akt via PI(3) kinase (Datta et al., 1996), we
examined whether the ras might suppress the HBx-
mediated apoptosis via Akt activation. To this end,
NIH3T3 cells were transiently transfected by various
expression plasmids as indicated, along with
pcDNA3.1-lacZ plasmid (Figure 3a). Two days after
transfection, apoptotic cells with dense nuclear staining
were counted as described (Miura et al., 1993). As
shown in in Figure 3a, it was found that approximately
12% of transfected cells were subjected to apoptosis by
HBx transfection. On the other hand, the ectopic
expression of H-ras suppressed the HBx-mediated
apoptosis significantly. When a dominant negative
mutant of Akt (Akt-dn, which is a kinase dead
mutant) was cotransfected into cells along with HBx
and the ras, the number of apoptotic cells was
increased to a level similar to that in HBx only
transfected cells. This result suggested that the
suppression of the HBx-mediated apoptosis by H-ras
was inhibited by Akt inactivation. In contrast,
cotransfection of the Akt-dn with HBx did not increase
apoptosis relative to that of HBx alone. In addition, H-
ras alone did not induce significant level of apoptosis,
whereas cotransfection of the Akt-dn with H-ras did
increase apoptosis. Thus, it seems that anti-apoptotic
signal triggered by H-ras was suppressed by the Akt-
dn.
Similarly, we next examined the involvement of the
PI(3)-Akt pathway in the suppression of the apoptosis
by treatment of cells with Wortmannin, a potent
inhibitor of PI(3) kinase. Consistent with the above
result, Wortmannin treatment suppressed the protec-
tive eect of activated H-ras, as Wortmannin treatment
in HBx plus H-ras transfected cells enhanced apoptosis
to a level similar to that in HBx transfected cells
(Figure 3b). However, Wortmannin treatment did not
aect the apoptosis induced by HBx. In addition,
Wortmannin treatment did increase the apoptosis of
cells transfected by H-ras. Similar to those of ectopic
expression of Akt-dn, it is possible that Wortmannin
treatment inhibited the survival signal triggered by H-
ras. Taken together, data obtained are consistent with
Figure 3 Evidence that the activation of Akt is involved in the
inhibition of HBx induced apoptosis by H-ras. (a) Transient
transfection assay to examine the eect of Akt-dn on the
apoptosis. NIH3T3 cells were transiently transfected with 0.3 mg
of pcDNA3.1-lacZ (Invitrogen) plus various combinations of the
indicated plasmids: 0.7 mg each of pSV-X, pEJ 6.6 (H-ras), or
pcDNA-Akt-dn. Akt-dn is a dominant negative mutant of Akt in
which its kinase domain is mutated. Two days after transfection,
apoptotic cells with dense nuclear staining were counted. (b)
Transient transfection assay to examine the eect of Wortmannin
on the apoptosis. Transfection was done as in panel (a), but some
cells were treated with Wortmannin (20 nM), a potent inhibitor of
PI(3)-kinase, as indicated. Four hours after transfection, cells
were treated with Wortmannin (20 nM) and incubated for another
48 h. Percentage of apoptotic cells with standard deviations from
triplicate cultures is indicated. Basal level of apoptosis observed in
the vector only control (* 10%) was subtracted
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a notion that the activated H-ras suppressed HBx-
mediated apoptosis via the PI(3) kinase-Akt pathway.
REF52 cells transfected by H-ras and HBx are fully
transformed
The observation that the HBx-mediated apoptosis was
suppressed by activated ras led us to examine the
transforming ability of HBx transfected rodent cells in
soft agar and in nude mice. It has been reported that
REF52 cells transfected either by ras or myc alone do
not form tumors in nude mice, whereas REF52 cells
transfected by both ras and myc can form tumors
(Franza et al., 1986). Therefore, we employed REF52
cells, which is an appropriate cell line for transforma-
tion assay. Thus, REF52 cells were transfected with
various test plasmids along with pSV2neo for selection.
Several colonies from each set of transfection were
picked and examined for morphological transformation
(Figure 4a). The G418-resistant colonies isolated from
HBx or H-ras transfected REF52 cells were morpho-
logically indistinguishable from parental REF52 cells.
In contrast, the morphology of HBx plus H-ras
transformants resembled cells transformed by H-ras
plus E1a, consisting of round and loosely adherent cells
(Figure 4a). Next, we tested four cell lines derived from
H-ras plus HBx transfection for anchorage-indepen-
dent growth in soft-agar (Table 2 and Figure 4b).
Three out of four REF52 cells transfected by both HBx
and H-ras formed colonies in soft agar, whereas the
cells transfected by either H-ras or HBx alone did not
(Table 2). As expected, the cells transfected by both H-
ras and E1a also grew in soft agar. Subsequently, the
tumor forming ability was tested by subcutaneously
injecting these REF52 cells into nude mice. Remark-
ably, nude mice injected with REF52 cells transfected
by both HBx and H-ras formed tumors. Three out of
four REF52-H-ras plus HBx cell lines injected into
nude mice gave rise to tumors (Table 2). On the other
hand, REF52 cells transfected with either H-ras or
HBx did not form any visible tumors. Thus, we
concluded that REF52 cells transfected by both HBx
and H-ras were fully transformed, as evidenced by
morphological transformation, anchorage-independent-
growth, and tumor formation in nude mouse.
Discussion
In this report, we provide direct evidence for the
contribution of HBx in tumorigenesis, in that activated
H-ras oncogene collaborates with HBx by suppressing
the HBx-mediated apoptosis. We examined the onco-
genic potential of HBx by colony formation assay
using NIH3T3 cells that is considered as a standard
cell line for transformation assay. Since HBx is present
at a very low copy number in hepatocytes of infected
animals (Dandri et al., 1996), we speculated that
overexpression of HBx might lead to a misinterpreta-
tion of outcomes. Thus, we employed the SV40
promoter to express HBx, instead of the strong CMV
Figure 4 Tumorigenicity of REF52 cells stably transfected by
HBx and H-ras. (a) Morphology of REF52 cells transformed by
the indicated oncogenes. Phase contrast photomicrographs of
transformed REF52 cells as well as parental REF52 cells. (b)
Anchorage-independence of HBx and H-ras transformed cells.
G418-resistant colonies recovered after transfection were plated
by layering single-cell suspensions (105 cells in 5 ml) in 0.37%
Noble agarose (Difco) on 60 mm plates containing 4 ml of 0.9%
Seakem agarose (FMC). Colonies (40.2 mm in diameter) were
counted after 21 days
Table 2 Transforming phenotypes of HBx and H-ras transfected
REF52 cells
Colony formation in
soft-agar (105 cells)a Tumorigenicity
Cell lines Exp. 1 Exp. 2 Exp. 3 in nude miceb
REF52-ras1 0 ndc 0 0/4
REF52-ras+E1a 2104 nd 1064 4/4
REF52-HBx 0 nd 0 0/4
REF52-ras+HBx1 nd 0 0 0/4
REF52-ras+HBx2 1488 3720 1896 4/4
REF52-ras+HBx3 nd 552 512 3/4
REF52-ras+HBx4 nd 2360 928 4/4
aThe number of cells forming colonies (40.2 mm) within 3 weeks
was counted. bTumorigenicity is expressed as the number of tumor
forming animals/number of injected animals. cnd, not determined
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promoter (Kim et al., 1998). Indeed, we found that H-
ras collaborated with HBx to transform cells by
suppressing HBx-mediated apoptosis. We demon-
strated that REF52 cells transfected by both H-ras
and HBx have transformed morphology and gained the
ability to grow on soft agar. Further, we demonstrated
the ability of HBx and H-ras transfected REF52 cells
to form tumors in nude mouse. To our knowledge, this
is the first experimental evidence that the contribution
of HBx to tumorigenesis is clearly demonstrated both
in cell culture and in vivo.
It was noted that HBx expression level is critical in
the decision as to whether cells are subjected to
apoptotic death (Terradillos et al., 1998). When HBx
was expressed from the strong CMV promoter,
collaboration of HBx with H-ras was not detected in
colony formation assay (Kim et al., 1998; Schuster et
al., 2000). Consistently, it has been reported that a low
level expression of HBx sensitizes cells to apoptotic
stimuli while overexpression of HBx triggers apoptotic
death in transfected cells (Terradillos et al., 1998). In
fact, HBx protein is hardly detectable in hepatocytes of
infected patients (Su et al., 1998). In woodchuck liver,
it has been convincingly demonstrated that HBx
protein level was extremely low (less than 40 000 –
80 000 molecules per cell) (Dandri et al., 1996). Thus,
the modest level of HBx expression from the SV40
promoter is more likely to reflect the physiological
eect of HBx in cells.
Several studies have indicated that HBx influences
cellular signaling pathways. It was reported that HBx
activates src (Klein and Schneider, 1997) and the ras/
raf/ERK (extracellular signal-regulated kinase) path-
way, which leads to transcriptional transactivation and
the stimulation of proliferation in quiescent cells (Benn
et al., 1996; Natoli et al., 1994). In addition, it was
reported that HBx activates c-Jun N-terminal kinases
(JNK) via MEKK-1 (MEK kinase) (Benn et al., 1996).
Subsequently, HBx has been implicated in both
deregulation of cell cycle control or cell proliferation
(Benn and Schneider, 1995; Koike et al., 1994b) and
apoptosis (Chirillo et al., 1997; Kim et al., 1998). Thus,
it appears that HBx has pleiotropic activities that may
or may not be related to oncogenesis. Signals
emanating from HBx expression trigger pleiotropic
biological outcomes, some of which, as in the case of
proliferation (ras/raf/ERK, src) and apoptosis (JNK),
may be contradictory. Related to this notion, we
interpreted our findings as to the suppression of the
HBx-mediated apoptosis by the activated H-ras leads
to stimulation of cell proliferation without subjecting
to apoptotic death, although our experiment did not
rule out a possibility that the activating Akt signaling
may contribute to cell proliferation via alternative
pathway, such as progression through G1/S arrest. The
net outcome of HBx expression is presumably dictated
by downstream interactions that independently potenti-
ate or mitigate each eector pathway in response to
other signals. Apoptosis normally eliminates cells with
damaged DNA, that is, those mostly likely to engender
a neoplastic clone. The proapoptotic activity of HBx
may contribute to viral oncogenesis by exerting a
selective pressure that favors the emergence of mutated
cells. Further studies on the mechanism of the HBx-
mediated apoptosis may provide new insights into the
mechanisms of viral persistence and pathogenesis as
well as the contribution of HBx in hepatocarcinogen-
esis.
Regarding collaboration with cellular oncogenes,
HBx has been shown to collaborate with c-myc for
tumor formation in transgenic mouse (Terradillos et
al., 1997). In this mouse model, HBx alone has no
direct pathological eect, but has accelerated tumor
formation induced by c-myc. Likewise, HBx expression
has been shown to lead to anchorage-independent
growth of AML12 cell line, mouse hepatocyte cell line
derived from TGF-a transgenic mouse (Tarn et al.,
1999). In these cells, it is presumed that either c-myc or
TGF-a collaborated with HBx to exhibit the trans-
forming phenotype. However, the molecular mechan-
isms by which c-myc or TGF-a collaborated with HBx
are not known. Taken together, it becomes apparent
that HBx is not acutely oncogenic, but contributes to
oncogenesis by stimulating proliferation of cells that
have already obtained additional mutation, such as the
activation of H-ras or c-myc.
Tumorigenesis is a multistage process, which in-
volves activation of cellular oncogenes and inactivation
of tumor suppressor genes. Cooperation between
oncogenes to transform cells is well-documented in
transformation of primary rodent cells. The initial
paradigm of this cooperation is the one between ras
and myc oncogene (Land et al., 1983). Subsequently, it
has been shown that Ela- or myc-induced apoptosis is
suppressed by ras (Kaumann-Zeh et al., 1997; Lin et
al., 1995), whereas the ras-induced senescence is
blocked by Ela or myc (Serrano et al., 1997). This
interaction is now understood as a molecular basis of
the collaboration between ras and myc. We propose
that along with adenovirus Ela and myc, HBx belongs
to a class of oncogenes, which alone induces apoptosis,




HBx expression plasmid, pSV-X, was a gift from CH Lee
(Spandau and Lee, 1988). The H-ras expression plasmid, pEJ
6.6(H-ras), was a gift from RA Weinberg (Land et al., 1983).
pRSV-myc, pE1a(13S), pcDNA-Akt-dn, and pCMV-Bcl-2
were obtained from Drs BS Yang, DS Im, J-K Jung and Y-J
Oh, respectively.
Cells and colony formation assay
NIH3T3 cells or Rat2 cells were transfected with 1 mg of
pSV-X, pEJ 6.6(H-ras), or pRSV-myc plasmid DNAs along
with 0.2 mg of pSV2neo plasmid DNA per 36105 cells/
60 mm plate as described (Franza et al., 1986). The total
amount of transfected DNA was kept constant using salmon
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sperm DNA as a carrier. At 20 h post-transfection, the cells
were split at a 1 : 3 or 1 : 4 ratio and cultured in the presence
of 200 mg per ml of G418. After 2 – 3 weeks of selection, the
cells were fixed in methanol: acetone (1 : 1) solution for
10 min, stained with 0.1% Giemsa in 6% methanol for
10 min, and the number of colonies was counted. REF52
cells were transfected by calcium phosphate precipitation with
5 mg of pSV-X, pEJ 6.6(H-ras), or pE1a(13S) DNAs along
with 1.0 mg of pSV2neo DNAs per 16106 cells/100 mm plate.
At 20 h post-transfection, the cells were washed in PBS and
cultured in the presence of 50 mg/ml of G418. After 3 weeks
of selection, G418-resistant colonies were isolated.
Viable cell counts
Cells were plated in DMEM containing 5% FBS at a density
of 36105 cells/60 mm plate. Next day, the cells were washed
and fed with DMEM containing 5% or 1% FBS and the
indicated amount of etoposide. After another 24 h of
incubation, the cells were washed and stained in PBS
containing 0.04% trypan blue solution. The viable cells
(trypan blue excluded) were counted with a hemacytometer.
DNA fragmentation analysis
DNA fragmentation assay was done as described (Hock-
enbery et al., 1990). Briefly, cells were plated in DMEM
containing 5% FBS at a density of 16106 cells per 100 mm
plate. Next day, the cells were treated with 10 mM of
etoposide for an additional 1 day. Both adherent and floating
cells were collected and incubated in ice-cold lysis buer
(0.5% Triton X-100, 5 mM Tris, pH 7.4, 20 mM EDTA) for
30 min. The lysates were centrifuged at 12 000 r.p.m. for
15 min, and the supernatant was transferred to a new tube.
DNA was extracted by phenol extraction and ethanol
precipitation and subjected to electrophoresis in 1.4%
agarose gels at 60 V for 6 h.
Transient apoptosis assay
NIH3T3 cells (16105) were seeded in each well of 12-well
plates. Next day, cells were transiently transfected with 0.3 mg
of pcDNA3.1-lacZ (Invitrogen) plus various expression
plasmids. Salmon sperm DNA was used to adjust total
DNA to equal amount. Two days after transfection,
apoptotic cells with dense nuclear staining were counted as
described (Miura et al., 1993).
Soft agar assay
G418-resistant colonies recovered after transfection were
tested for anchorage-independent growth as described (Kohl
and Ruley, 1987). Cells were plated by layering single-cell
suspension (105 cells in 5 ml) in 0.37% Noble agarose (Difco)
on 60 mm plates containing 4 ml of 0.9% Seakem agarose
(FMC). Agarose layers contained DMEM supplemented with
10% FBS. Cells were fed weekly by addition of 5 ml of
media containing 0.37% agarose. To facilitate colony
counting, the 60 mm plate was divided into four parts and
only one part was counted.
Tumor formation in nude mice
Tumorigenicity of transfected cell lines was measured as
follows. Cells were harvested by trypsinization, washed twice
with sterile phosphate-buered saline, and resuspended at
26107 cells per ml. Aliquots (0.1 ml) were injected sub-
cutaneously into 6- to 8-week-old Balb/c athymic nude mice.
Mice were observed at periodic intervals. The photograph
was taken at 3 weeks after injection.
Western blot analysis
Equal amounts of whole cell protein extracts were resolved
by 15% SDS–PAGE, transferred to nitrocellulose, immuno-
blotted with rabbit polyclonal anti-HBx peptide (carboxy-
terminal of HBx peptide, residue 144 – 154), visualized with
the ECL system (Amersham).
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